**5. Conclusion**

Malignant glioma, especially GBM, is still a devastating cancer in CNS. Despite of intensive treatment with neurosurgical resection, radiotherapy, and adjuvant chemotherapy with TMZ, the median survival is less than 2 years. Development of novel strategies against malignant gliomas is of urgent necessity. The advent of interstitial chemotherapy has definitely in‐ creased treatment options for patients with malignant glioma. Local delivery of chemothera‐ peutic agents bypasses the physiological barrier of normal brain, achieving a significantly increased concentration in targeted sites and a minimized systemic toxicity. Gliadel® wafers represent the success of interstitial chemotherapy for malignant gliomas. On the other hand, CED is a promising approach for local drug delivery, but improvement in the techniques is required. In addition, novel methods such as micro‐chips and gene delivery is under investi‐ gation (80). In a word, interstitial chemotherapy conveys the opportunity of more efficiently and effectively delivering anti‐glioma agents to the infiltrative tumors than conventional routes of administration.
